金戈莱德作为阿尔茨海默病的有前途的多重目标治疗药物:针对ApoE4和超越的目标
Saba Beigh1, Mansoor Alsahag2, Ali Alisaac2
1Department of Public Health, Faculty of Applied Medical Sciences, Al-Baha University, Al-Baha, Saudi Arabia.
Current pharmaceutical design
|August 4, 2025
概括
银戈利德作为阿尔茨海默氏症治疗方法具有前景,因为它有效地与ApoE4结合,ApoE4是关键的遗传风险因素. 它强大的结合亲和力和有利的药理动力学表明,与其他天然化合物相比,它具有更高的治疗潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 计算化学计算化学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特征是神经炎症,粉样β斑块和认知能力下降.
- 目前的AD治疗只能提供症状缓解,强调需要新的多目标治疗策略.
- 脂蛋白E4 (ApoE4) 是阿尔茨海默氏症的主要遗传风险因素,使其成为一个有前途的治疗点.
研究的目的:
- 调查天然化合物金戈利德作为阿尔茨海默氏症多目标治疗剂的潜力.
- 阐明金戈利德与阿波利波蛋白E4 (ApoE4) 的N端域之间的相互作用.
- 为了评估ginkgolide在中的结合亲和力,稳定性和药理动力学特性.
主要方法:
- 用分子对接和分子动力学 (MD) 模拟来评估金金戈利德和ApoE4 (PDB ID: 8AX8) 之间的相互作用.
- 使用AutoDock Vina确定了结合亲和力,并通过100 ns MD模拟评估了复杂稳定性.
- 使用瑞士ADME和PkCSM预测了药理动力学特性和毒性,与黄素和白醇进行了比较对接.
主要成果:
- 银戈利德对ApoE4表现出显著的结合亲和力 (-7.1 kcal/mol),形成稳定的疏水接触.
- MD模拟证实了银甲-ApoE4复合物的稳定性超过100个纳秒,波动最小.
- 在体中,药理动力学预测表明,金戈利德的吸收良好,血脑屏障透,没有显著的毒性风险.
结论:
- 银戈利德有效地结合和稳定ApoE4 N-终端域,这表明它在调节关键的AD病理因素方面发挥了作用.
- 与黄素和白醇相比,银戈利德表现出更高的结合亲和力和稳定性,这表明其治疗潜力更大.
- 这些发现支持金金戈利德作为潜在的多目标AD治疗方法,并强调在早期药物发现中使用in silico方法的实用性.
更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.1K
06:40Quantitative Measurement of γ-Secretase-mediated Amyloid Precursor Protein and Notch Cleavage in Cell-based Luciferase Reporter Assay Platforms
Published on: January 25, 2018
6.9K
相关概念视频
01:22Alzheimer's Disease: Treatment
262
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
262
01:26Alzheimer's Disease: Overview
669
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
669
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.6K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
650
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
650
01:15G Protein-coupled Receptors
13.4K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.4K